The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
New strategies for clinical trials in patients with sepsis and septic shock
Abstract
OBJECTIVE: The difficulty in identifying new treatment modalities that significantly reduce the mortality and morbidity rates associated with sepsis has highlighted the need to reevaluate the approach to clinical trial design. The United Kingdom Medical Research Council convened an International Working Party to address these issues. DATA SOURCES: The subject areas that were to be the focus of discussion were identified by the co-chairs, and group leaders were nominated. Preconference reading material was circulated to group members. STUDY SELECTION AND DATA EXTRACTION: Small-group discussion fed into an iterative process of feedback from plenary sessions, followed by the formulation of recommendations. Finally, each working group prepared a summary of its recommendations and these are reported herein. DATA SYNTHESIS: There were five key recommendations. First, investigators should no longer rely solely on the American College of Chest Physicians/Society of Critical Care Medicine definitions of sepsis or sepsis syndrome as the basis of trial entry. Entry criteria should be based on three principles: a) All patients should have infection; b) there should be evidence of a pathologic process that represents a biologically plausible target for the proposed intervention, for example, an abnormal circulating level of a biological marker pertinent to the study drug; and c) patients should fall into an appropriate category of severity (usually severe sepsis). Second, investigators should use a scoring system for organ dysfunctions that has been validated and that can be incorporated into all sepsis studies; agreement on the use of a single system would simplify comparisons between studies. Third, the primary outcome measure generally should be mortality rates, but under appropriate circumstances major morbidities could be considered as primary end points. Regardless of choice of the duration to primary end point, patients should be followed for > or =90 days. Fourth, sample size needs to be based on a realistic assessment of achievable effect size based on knowledge of the at-risk population. Fifth, subgroups should be few in number and should be defined a priori on the basis of variables present before randomization. CONCLUSIONS: Important changes in several aspects of trial design may improve the quality of clinical studies in sepsis and maximize the chance of identifying effective therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190
Annane, D. (2000) · JAMA · doi:10.1001/jama.283.8.1038 · Cited by 1,000 · cited 1×
“Another example would be documentation of an impaired hypothalamic-pituitaryadrenal axis before randomization in trials of corticosteroid therapy (23).”
BackgroundTreating Patients with Severe Sepsis
Wheeler, A. P., & Bernard, G. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400307 · Cited by 992
Self-citation
Cited by
Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care
Myburgh, J. A., Finfer, S., Bellomo, R., Billot, L., Cass, A., Gattas, D., Glass, P., Lipman, J., Liu, B., McArthur, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209759 · Cited by 1,687
Animal Models of sepsis: setting the stage
Buras, J. A., Holzmann, B., & Sitkovsky, M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1854 · Cited by 843
Kellum, J. A. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.15.1655 · Cited by 828
Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis
Bozza, F. A., Salluh, J. I., Japiassu, A. M., Soares, M., Assis, E. F., Gomes, R. N., Bozza, M. T., Castro-Faria-Neto, H. C., & Bozza, P. T. (2007) · Critical Care · doi:10.1186/cc5783 · Cited by 740
Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis
Fergusson, D., Aaron, S. D., Guyatt, G., & Hébert, P. (2002) · BMJ · doi:10.1136/bmj.325.7365.652 · Cited by 708
Self-citation
Metadata
- Authors
- Cohen, J., Guyatt, G., Bernard, G. R., Calandra, T., Cook, D., Elbourne, D., Marshall, J., Nunn, A., & Opal, S.
- Venue
- Critical Care Medicine
- Published
- 2001-04
- Volume
- 29
- Issue
- 4
- Pages
- 880-886
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2010982832
- Cited by
- 158
- References
- 4
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New strategies for clinical trials in patients with sepsis and septic shock. https://app.cochat.ai/papers/10.1097/00003246-200104000-00039
- The paper
- Cohen, J., Guyatt, G., Bernard, G. R., Calandra, T., Cook, D., Elbourne, D., Marshall, J., Nunn, A., & Opal, S. (2001). New strategies for clinical trials in patients with sepsis and septic shock. Critical Care Medicine. https://doi.org/10.1097/00003246-200104000-00039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.